|
COG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.00199999911277E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.5343999948978E-08 |
| Normal-vs-Stage2 |
1.599950E-01 |
| Normal-vs-Stage3 |
9.62749999722234E-08 |
| Normal-vs-Stage4 |
4.38310000516751E-08 |
| Stage1-vs-Stage2 |
8.561900E-03 |
| Stage1-vs-Stage3 |
5.809200E-01 |
| Stage1-vs-Stage4 |
2.283200E-01 |
| Stage2-vs-Stage3 |
7.761300E-03 |
| Stage2-vs-Stage4 |
3.197000E-03 |
| Stage3-vs-Stage4 |
5.416600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.84359999488848E-08 |
| Normal-vs-AfricanAmerican |
1.971900E-02 |
| Normal-vs-Asian |
1.8371000054529E-08 |
| Caucasian-vs-AfricanAmerican |
2.117000E-01 |
| Caucasian-vs-Asian |
1.589220E-01 |
| AfricanAmerican-vs-Asian |
2.095700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60235999999703E-05 |
| Normal-vs-Female |
1.34959999953388E-07 |
| Male-vs-Female |
7.635800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.92429999607202E-09 |
| Normal-vs-Age(41-60Yrs) |
8.74169999720564E-08 |
| Normal-vs-Age(61-80Yrs) |
7.322500E-03 |
| Normal-vs-Age(81-100Yrs) |
2.343500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.415800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.020900E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.704800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.913600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.335400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.988600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.838420E-02 |
| Classical-VS-Follicular |
8.517700E-03 |
| Classical-VS-Other |
5.534800E-01 |
| Classical-VS-Normal |
3.48809999772826E-08 |
| Tall-VS-Follicular |
2.249800E-04 |
| Tall-VS-Other |
7.774800E-01 |
| Tall-VS-Normal |
9.14910003313452E-09 |
| Follicular-VS-Other |
1.936770E-01 |
| Follicular-VS-Normal |
1.240130E-02 |
| Other-VS-Normal |
6.830400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.51679999999188E-06 |
| Normal-vs-N1 |
4.77784478647436E-12 |
| N0-vs-N1 |
5.81060000000022E-05 |
|
|
